Atma (Sambucus) tablets №36

1 tablet contains: active ingredients: Sambucus nigra D1 35.7 mg, Natrium sulfuricum D6 37.2 mg, Solanum dulcamara D6 37.2 mg, Arsenicum album D12 37.2 mg, Tartarus emeticus D12 37.2 mg

excipients: lactose, potato starch, magnesium stearate.

Pills.

Round flat tablets from white to slightly greenish-brown in color with possible splashes of green and brownish color with a dividing line.

Complex homeopathic preparation.

Atma (Sambucus) tablets have a systemic therapeutic effect due to the combination and mutual enhancement of the action of the active components. It has a bronchodilator, mucolytic, anti-inflammatory, immunomodulatory and anti-allergic effect.

The drug eliminates spasm and reduces the reactivity of the bronchi, reduces shortness of breath, reduces the frequency and intensity of asthma attacks. Improves quantitative (production volume) and qualitative (physico-chemical) characteristics of sputum, promotes liquefaction and more efficient discharge of thick mucus. Restores the work of the ciliated epithelium of the bronchi.

The anti-inflammatory effect of the drug prevents damage to the bronchi and lungs by free radicals and proteases, protects the pulmonary blood flow from the action of inflammatory mediators.

Reduces inflammatory infiltration and swelling of the mucous membrane, prevents sclerotic changes in the bronchi and lungs. It improves systemic immunity, normalizes the functional state of the cellular link and indicators of humoral immunity (IgE level and CEC), and also reduces antigenic stimulation. Helps stabilize mast cell membranes, reduces eosinophilia.

Increases the effectiveness of complex treatment of bronchial asthma. Enhances the bronchodilator effect of inhaled corticosteroids and β2-agonists, reduces the period of admission or dose of these basic therapy drugs. In the treatment of bronchitis, including obstructive, the drug reduces broncho-obstructive syndrome, improves the dynamics of clinical (including auscultatory symptoms, respiratory function, peak flow data) and subjective manifestations. In the treatment of chronic bronchitis, including smoker’s cough, the drug facilitates coughing, improves breathing, general condition and quality of life, prevents the development of irreversible changes in the bronchi and lungs. Provides rapid elimination of asthenic symptom complex of hypoxic and infectious genesis. Stimulates the individual compensatory capabilities of the body, increases the nonspecific reactivity of the body to infections. Improves psychometric parameters of the quality of life of patients.